Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Heather G.

Neumora Therapeutics, Inc. Common Stock

Therini Bio develops immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. It focuses on a clinical-stage pipeline aimed at treating severe neurological and retinal diseases.

Therini Bio

Brain diseases collectively represent one of the largest areas of unmet medical need, affecting upwards of 1.5 billion patients globally. Neumora was founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our goal is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.

We’ve built a pipeline comprised of programs for neuropsychiatric disorders and neurodegenerative diseases, each targeting a novel mechanism of action where we can leverage our precision neuroscience approach. Our pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. 

Neumora is committed to addressing some of the most prevalent brain health disorders and transforming the standard of care for millions of patients living with brain diseases. Learn more about Neumora and career opportunities on our website below.

Mubadala Capital Ventures

Invus

Abu Dhabi Growth Fund

Altitude Life Science Ventures

Amgen

EXOR N.V.

ARCH Venture Partners

Newpath Management

Polaris Partners

F-Prime Capital

Neumora

We are delighted to welcome Kaya Pai Panandiker as Chief Commercial Officer. Kaya brings to Neumora extensive commercial strategy and execution expertise, having led the launches of multiple neuropsychiatry products throughout her career. Read more: https://lnkd.in/ex-Zr2JP

Each year, our CEO Excellence Awards celebrate individuals or cross functional teams who demonstrate our values every day by achieving the extraordinary, creating value and doing what is right. We were thrilled to recognize our 2023 winners, Karla Zeitz, Jason Morton, Partha Mudipalli, Ph.D., Hong Ji, Santnu P., Michael Eyre, Heather Stemper, Palwasha T., Leanna Bui, Tash Barrow, Kelly Voong and Anh Le Vynh, for their outstanding contributions to Neumora. Thank you for your unwavering dedication to this work!

We’ve had a great week connecting with #JPM24 attendees! #ICYMI, check out CEO Henry Gosebruch’s podium presentation, outlining the exciting year ahead and our industry-leading pipeline. We look forward to continuing to pioneer a new era in brain disease and lead innovation in brain health throughout 2024. https://lnkd.in/eRFzBnEY

Neumora was founded to improve the lives of people living with brain diseases. To do that, we’ve built an industry-leading pipeline comprised of programs for neuropsychiatric disorders and neurodegenerative diseases, each targeting a novel mechanism of action. Learn more about our pipeline below. #JPM24

We are heading to San Francisco next week for #JPM24! CEO Henry Gosebruch will present on Monday, January 8 at 11:15AM PT. Learn more below. https://lnkd.in/ePiU73Zx

We are headed into this holiday season filled with gratitude for those around us. Wishing you the happiest of holidays from all of us at Neumora!

A recent NAMI study found that 64% of people with a mental illness said holidays make their conditions worse. It's important to put yourself first and prioritize your well-being, especially during the holiday season. We're sharing some of our favorite tips from NAMI and The Jed Foundation (JED) on how to reduce stress and maintain good #mentalhealth in the coming weeks. In an emergency, dial 988 to reach the suicide and crisis lifeline.

We are pleased to welcome Jason G. Duncan to Neumora as Chief Legal Officer. Jason's decades of legal, compliance, development and operations experience will be invaluable to our team as we continue to progress our pipeline. Read more: https://lnkd.in/eUdk_Gkr

We had a great time in Tampa at #ACNP2023, where Dr. Sanjay Mathew presented data from our #MDD program. It was great to connect with so many neuropsych thought leaders!

Today we announced IND clearance and the initiation of a Phase 1 study for NMRA-266, our M4 positive allosteric modulator. Read more here. https://lnkd.in/e_Vz_cjb

Metric
Company Name	Neumora Therapeutics, Inc. Common Stock	Therini Bio
Symbol	NMRA
MSH ID	COM:NEUMORATX	COM:THERINIBIO
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	US
Stage	Series B
Employee Count	120
Website	neumoratx.com	therinibio.com
LinkedIn	neumora	therinibio
Founders

Metric
Market Cap	1.72B
Enterprise Value
Monthly Web Traffic	6.75K
Web Traffic Growth	0.17
Valuation
Raised Capital	112M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:NEUMORATX

Neumora Therapeutics, Inc.

Last Close

9.69

22/11 21:00

Market Cap

1.72B

Beta: -

Volume Today

490.17K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue